Thelansis

Congenital Disorder of Glycosylation Type 1a Market Outlook Thelansis’s “Congenital Disorder of Glycosylation Type 1a Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Disorder of Glycosylation Type 1a treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which e...

Congenital Disorder of Glycosylation Type 1a Market Outlook Thelansis’s “Congenital Disorder of Glycosylation Type 1a Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Congenital Disorder of Glycosylation Type 1a treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Congenital Disorder of Glycosylation Type 1a Overview Congenital disorder of glycosylation type 1a is an inherited disease characterized by variable developmental delays as well as muscle and bone problems that worsen with age. Individuals with glycosylation disorder type 1a have phosphomannomutase 2 enzyme deficiencies. CDG-Ia is related to deficient phosphomannomutase ac...

  Congenital disorder of glycosylation type 1a is an inherited disease characterized by variable developmental delays as well as muscle and bone problems that worsen with age. Individuals with glycosylation disorder type 1a have phosphomannomutase 2 enzyme deficiencies. CDG-Ia is related to deficient phosphomannomutase activity and represents 80% of CDG type I. The enzyme is coded by PMM2, a gene situated in chromosomal segment 16p13. Gastrointestinal and neurologic symptoms predominate in the neonatal period and infancy. The most important features during childhood are hypotonia, ataxia, mental retardation, joint contractures, and pigmentary retinopathy. It is estimated that 20% of patients die during the first year of life due to severe infection, liver insufficiency or cardiomyopathy. The prevalence of Congenital disorder of glycosylation type 1a ranges from 1 to 2 cases in 200,000 newborn population in the USA.   Thelansis’s “Congenital Disorder of Glycos...